JPRN-UMIN000011423已完成1 期
Phase I study of a therapeutic vaccine in ATL patients with autologous dendritic cells pulsed with Tax peptides - Phase I study of Tax specific DC vaccine for ATL patients
ational Hospital Organization Kyushu Cancer Center0 个研究点目标入组 6 人开始时间: 2013年8月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with severe complications: cardiovascular disorders, respiratory disorders, renal dysfunction, immunodeficiency, hematological disorders, autoimmune diseases, sever allergy and severe infectious disease. 2) Patients who should receive systemic administration of steroid or immunosuppressive agents. 3) Presence of active brain metastases 4) Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant 5) Severe psychiatric disorder 6) History of HAM/TSP 7) Active multiple cancers 8) Inappropriate for study entry judged by an attending physician
研究者
相似试验
进行中（未招募）
不适用
Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.Prostatic cancer patients who have received curative surgery.EUCTR2010-018770-20-NOOslo University Hospital30
进行中（未招募）
1 期
Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanomaEUCTR2008-006253-41-NOThe Norwegian Radium Hospital, Oslo University Hospital25
进行中（未招募）
1 期
oGlioblastoma is the most common primary brain tumour in humans withthe most severe prognosis. Standard treatments consist primarily ofsurgery in order to debulk thetumoral mass, as well asradiochemotherapy to induce optimal local tumor control. However themedian overall survival (OS)is about 15 months, with 88% of patientsdead within 3 yearsMedDRA version: 18.0Level: HLTClassification code 10045172Term: Tumour vaccine therapiesSystem Organ Class: 100000004865EUCTR2013-005387-25-ITSapienza, University of Rome10
进行中（未招募）
1 期
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of theChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.HIV InfectionCTIS2024-514581-39-00Ospedale San Raffaele S.r.l.33
已完成
1 期
Phase I/II study of a novel peptide vaccination therapy, CDCA1 and KOC1, for previously treated advanced non-small-cell lung cancerpreviously treated advanced non-small-cell lung cancerJPRN-UMIN000005087Showa University School of Medicine26